This is a preview of subscription content, log in via an institution to check access.
Notes
2020 US dollars
Reference
Peng Y, et al. First-Line Atezolizumab for Metastatic NSCLC with High PD-L1 Expression: A United States-Based Cost-Effectiveness Analysis. Advances in Therapy : 5 Apr 2021. Available from: URL: http://doi.org/10.1007/s12325-021-01734-6
Rights and permissions
About this article
Cite this article
Atezolizumab not cost effective for NSCLC with high PD-L1 expression. PharmacoEcon Outcomes News 876, 7 (2021). https://doi.org/10.1007/s40274-021-7621-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7621-3